OQS
NTLA icon

Occudo Quantitative Strategies’s Intellia Therapeutics NTLA Stock Holding History

Occudo Quantitative Strategies’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-18,610
Closed -$1.04M – 1240
2022
Q3 		$1.04M Sell
18,610
-44,447
-70% -$2.76M 0.08% 381
2022
Q2 		$3.26M Buy
63,057
+33,682
+115% +$1.71M 0.27% 89
2022
Q1 		$2.13M Buy
+29,375
New +$2.49M 0.18% 158
2021
Q1 		– Sell
-7,291
Closed -$397K – 873
2020
Q4 		$397K Buy
+7,291
New +$265K 0.12% 324

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Occudo Quantitative Strategies's NTLA Position: Q4 2022 in Review

Occudo Quantitative Strategies sold out of Intellia Therapeutics (NTLA) in Q4 2022, closing a stake of 18,610 shares — an estimated $1.04M sold.

Occudo Quantitative Strategies first reported a position in NTLA in Q4 2020 and held it in 4 quarters. The position peaked at $3.26M in Q2 2022. 303 funds tracked by Wall St. Rank hold NTLA as of Q4 2022.

  • Occudo Quantitative Strategies reported no remaining Intellia Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Occudo Quantitative Strategies sold 18,610 Intellia Therapeutics shares in Q4 2022, an estimated $1.04M.
  • Occudo Quantitative Strategies first reported a position in Intellia Therapeutics in Q4 2020 and held it in 4 quarters.
  • Occudo Quantitative Strategies's Intellia Therapeutics position peaked at $3.26M in Q2 2022.
  • 303 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2022.

Based on Occudo Quantitative Strategies's 13F filing for Q4 2022, filed 14 Feb 2023.